Furthermore, recent immunotherapies targeting specific immune checkpoints such as PD-1/L1 and CTLA4 have shown promising results in colon cancer treatment, suggesting that the tumor microenvironment plays an important role [31, 32]. This evidence concerns the gene CTLA4 and neoplasm.